TY - JOUR
T1 - Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan
AU - and Japan RCC Trialist Collaborative Group (JRTCG) investigators
AU - Eto, Masatoshi
AU - Kawano, Yoshiaki
AU - Hirao, Yoshihiko
AU - Mita, Koji
AU - Arai, Yoichi
AU - Tsukamoto, Taiji
AU - Hashine, Katsuyoshi
AU - Matsubara, Akio
AU - Fujioka, Tomoaki
AU - Kimura, Go
AU - Shinohara, Nobuo
AU - Tatsugami, Katsunori
AU - Hinotsu, Shiro
AU - Naito, Seiji
N1 - Publisher Copyright:
© 2015 Eto et al.
PY - 2015/10/9
Y1 - 2015/10/9
N2 - Background: To improve antitumor effects against metastatic renal cell carcinoma (mRCC), use of molecular target-based drugs in sequential or combination therapy has been advocated. In combination therapy, interferon (IFN)-aα amplified the effect of sorafenib in our murine model (J Urol 184:2549, 2010), and cytokine-treated mRCC patients in Japan had good prognoses (Eur Urol 57:317, 2010). We thus conducted a phase II clinical trial of sorafenib plus IFN-aα for untreated mRCC patients in Japan. Methods: In this multicenter, prospective study, provisionally registered patients with histologically confirmed metastatic clear cell RCC received natural IFN-aα (3 dosages of 3 million U per week) for 2 weeks. Only IFN-aα-tolerant patients were registered to this trial, and treated additionally with oral sorafenib (400 mg, bid). The primary end point of the study was rate of response (CR + PR) to sorafenib plus IFN-aα treatment assessed using RECIST v1.0. The secondary end points were disease control rate (CR + PR + SD), progression free survival (PFS), overall survival (OS), and safety of the combined treatment. PFS and OS curves were plotted using the Kaplan-Meier method. Results: From July 2009 to July 2012, a total of 53 untreated patients were provisionally registered, and 51 patients were finally registered. Rate of Response to the combined therapy of sorafenib plus IFN-aα was 26.2 % (11/42) (CR 1, PR 10). The median PFS was 10.1 months (95 % CI, 6.4 to 18.5 months), and the median OS has not been reached yet. The combined therapy increased neither the incidence of adverse effects (AE) nor the incidence of unexpected AE. A limitation was that a relatively high number of patients (9 patients) were excluded for eligibility criteria violations. Conclusion: Our data have demonstrated that sorafenib plus IFN-aα treatment is safe and effective for untreated mRCC patients. Trial registration:UMIN000002466 , 9th September, 2009
AB - Background: To improve antitumor effects against metastatic renal cell carcinoma (mRCC), use of molecular target-based drugs in sequential or combination therapy has been advocated. In combination therapy, interferon (IFN)-aα amplified the effect of sorafenib in our murine model (J Urol 184:2549, 2010), and cytokine-treated mRCC patients in Japan had good prognoses (Eur Urol 57:317, 2010). We thus conducted a phase II clinical trial of sorafenib plus IFN-aα for untreated mRCC patients in Japan. Methods: In this multicenter, prospective study, provisionally registered patients with histologically confirmed metastatic clear cell RCC received natural IFN-aα (3 dosages of 3 million U per week) for 2 weeks. Only IFN-aα-tolerant patients were registered to this trial, and treated additionally with oral sorafenib (400 mg, bid). The primary end point of the study was rate of response (CR + PR) to sorafenib plus IFN-aα treatment assessed using RECIST v1.0. The secondary end points were disease control rate (CR + PR + SD), progression free survival (PFS), overall survival (OS), and safety of the combined treatment. PFS and OS curves were plotted using the Kaplan-Meier method. Results: From July 2009 to July 2012, a total of 53 untreated patients were provisionally registered, and 51 patients were finally registered. Rate of Response to the combined therapy of sorafenib plus IFN-aα was 26.2 % (11/42) (CR 1, PR 10). The median PFS was 10.1 months (95 % CI, 6.4 to 18.5 months), and the median OS has not been reached yet. The combined therapy increased neither the incidence of adverse effects (AE) nor the incidence of unexpected AE. A limitation was that a relatively high number of patients (9 patients) were excluded for eligibility criteria violations. Conclusion: Our data have demonstrated that sorafenib plus IFN-aα treatment is safe and effective for untreated mRCC patients. Trial registration:UMIN000002466 , 9th September, 2009
KW - Interferon-alpha
KW - Renal cell carcinoma
KW - Sorafenib
UR - http://www.scopus.com/inward/record.url?scp=84943818598&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84943818598&partnerID=8YFLogxK
U2 - 10.1186/s12885-015-1675-1
DO - 10.1186/s12885-015-1675-1
M3 - Article
C2 - 26452347
AN - SCOPUS:84943818598
VL - 15
JO - BMC Cancer
JF - BMC Cancer
SN - 1471-2407
IS - 1
M1 - 667
ER -
